Compare BLX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLX | PGEN |
|---|---|---|
| Founded | 1977 | 1998 |
| Country | Panama | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1997 | 2013 |
| Metric | BLX | PGEN |
|---|---|---|
| Price | $50.26 | $3.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 115.7K | ★ 4.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $13.11 | $342.78 |
| Revenue Next Year | $10.13 | $478.46 |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.14 | $1.11 |
| 52 Week High | $51.99 | $5.47 |
| Indicator | BLX | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.79 | 33.80 |
| Support Level | $43.50 | $3.49 |
| Resistance Level | $51.99 | $5.10 |
| Average True Range (ATR) | 1.33 | 0.36 |
| MACD | -0.12 | -0.13 |
| Stochastic Oscillator | 52.73 | 1.57 |
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.